Tonix Pharmaceuticals enrolls first patient in pivotal Phase 2 HORIZON trial for TNX-102 SL in MDD

Tonix Pharmaceuticals announced first patient enrolled in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder.Key Highlights:Original SEC Filing: Tonix Pharmaceuticals Holding Corp. [ TNXP ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain ina…

Tonix Pharmaceuticals announced first patient enrolled in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder.

Key Highlights:

First participant enrolled in HORIZON, a randomized, double-blind, placebo-controlled Phase 2 trial of TNX-102 SL 5.6 mg for MDD.
Study is 6 weeks, aims to enroll ~360 patients at ~30 U.S. sites; primary endpoint is change in MADRS total score at Week 6.
TNX-102 SL targets sleep quality via multi-receptor antagonism; company cites prior signals in PTSD and fibromyalgia studies.
TNX-102 SL is FDA-approved for fibromyalgia (TONMYA) and has U.S. patents expected to provide market exclusivity through 2034.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.